AU2000234451B2 - Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists - Google Patents

Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists Download PDF

Info

Publication number
AU2000234451B2
AU2000234451B2 AU2000234451A AU2000234451A AU2000234451B2 AU 2000234451 B2 AU2000234451 B2 AU 2000234451B2 AU 2000234451 A AU2000234451 A AU 2000234451A AU 2000234451 A AU2000234451 A AU 2000234451A AU 2000234451 B2 AU2000234451 B2 AU 2000234451B2
Authority
AU
Australia
Prior art keywords
receptor
carboxy
substituted
optionally substituted
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2000234451A
Other languages
English (en)
Other versions
AU2000234451A1 (en
Inventor
Gordon Smith Baxter
Robert Alexander Coleman
Nicholas Tilford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision for Medicine (UK Labs) Ltd
Original Assignee
Asterand UK Acquisition Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand UK Acquisition Ltd filed Critical Asterand UK Acquisition Ltd
Publication of AU2000234451A1 publication Critical patent/AU2000234451A1/en
Application granted granted Critical
Publication of AU2000234451B2 publication Critical patent/AU2000234451B2/en
Assigned to ASTERAND UK LIMITED reassignment ASTERAND UK LIMITED Request for Assignment Assignors: PHARMAGENE LABORATORIES LTD
Assigned to ASTERAND UK ACQUISITION LIMITED reassignment ASTERAND UK ACQUISITION LIMITED Request for Assignment Assignors: ASTERAND UK LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2000234451A 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists Ceased AU2000234451B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/001138 WO2001072302A1 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Publications (2)

Publication Number Publication Date
AU2000234451A1 AU2000234451A1 (en) 2001-12-20
AU2000234451B2 true AU2000234451B2 (en) 2005-09-29

Family

ID=9883925

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2000234451A Ceased AU2000234451B2 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
AU3445100A Pending AU3445100A (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3445100A Pending AU3445100A (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Country Status (8)

Country Link
EP (1) EP1267867B1 (enExample)
JP (1) JP2003528144A (enExample)
AT (1) ATE395058T1 (enExample)
AU (2) AU2000234451B2 (enExample)
CA (1) CA2402099C (enExample)
DE (1) DE60038902D1 (enExample)
DK (1) DK1267867T3 (enExample)
WO (1) WO2001072302A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE371454T1 (de) * 2001-10-31 2007-09-15 Medical Res Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2679175C (en) * 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
AU9177698A (en) * 1997-09-25 2000-04-17 Asterand Uk Acquisition Limited Medicaments for the treatment of primary headache disorders and drug-induced headaches
AU6836200A (en) * 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0736018T3 (da) * 1993-12-20 2000-09-18 Fujisawa Pharmaceutical Co 4,5-Diaryloxazolderivater

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
AU9177698A (en) * 1997-09-25 2000-04-17 Asterand Uk Acquisition Limited Medicaments for the treatment of primary headache disorders and drug-induced headaches
AU6836200A (en) * 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer

Also Published As

Publication number Publication date
DK1267867T3 (da) 2008-08-25
AU3445100A (en) 2001-10-08
WO2001072302A1 (en) 2001-10-04
EP1267867B1 (en) 2008-05-14
CA2402099C (en) 2011-04-26
JP2003528144A (ja) 2003-09-24
CA2402099A1 (en) 2001-10-04
DE60038902D1 (de) 2008-06-26
EP1267867A1 (en) 2003-01-02
ATE395058T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
US8513027B2 (en) Method of identifying an inhibitor of the prostanoid EP4 receptor
Davis et al. EP4 prostanoid receptor‐mediated vasodilatation of human middle cerebral arteries
Takasu et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function
Chen et al. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody‐driven K/BxN serum–transfer arthritis
EP1267867B1 (en) Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
Foudi et al. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype
CA2415577C (en) Use of cox-2 inhibitors for preventing immunodeficiency
AU2000234451A1 (en) Use of prostanoid EP4 receptor antagonists for the treatment of headache and assays for such antagonists
BRPI0714593A2 (pt) antagonistas de receptores da subfamÍlia 3 (edg-3, s1p3) do gene de diferenciaÇço endotelial para a prevenÇço e tratamento de doenÇas oculares, composiÇÕes compreendendo os referidos antagonistas, e usos dos mesmos
JP2017507930A (ja) ＩＫＫε／ＴＢＫ１阻害剤とベータアドレナリン作動性アゴニストまたは交感神経系活性化剤との組合せ
Greig et al. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension
Hein et al. Functional and molecular characterization of the endothelin system in retinal arterioles
EP1047413B1 (fr) Composition pharmaceutique comprenant un inhibiteur spécifique de l'aminopeptidase a, en particulier l'ec33, pour diminuer la pression artérielle
AU2005218937B2 (en) Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
US20030158240A1 (en) Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US6319955B1 (en) Use of MEK1 inhibitors as protective agents against damage due to ischemia
TW200301257A (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
Centurión et al. The GR127935‐sensitive 5‐HT1 receptors mediating canine internal carotid vasoconstriction: resemblance to the 5‐HT1B, but not to the 5‐HT1D or 5‐ht1F, receptor subtype
Kim et al. Relaxation of rabbit middle cerebral arteries in vitro by H1 histaminergic agonists is inhibited by indomethacin and tranylcypromine
Kuo et al. NP‐313, 2‐acetylamino‐3‐chloro‐1, 4‐naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A2 synthesis and calcium entry
AU2001270902B2 (en) Use of COX-2 inhibitors for preventing immunodeficiency
JP2010047583A (ja) 原発性頭痛障害の治療のためのプロスタノイドアンタゴニストの使用
Potenza et al. Endothelial cyclo-oxygenase-1 and-2 differentially affect reactivity of mesenteric vascular bed in portal hypertensive rats
JP2021534141A (ja) アルコール使用障害の治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASTERAND UK LIMITED

Free format text: FORMER OWNER WAS: PHARMAGENE LABORATORIES LTD

PC Assignment registered

Owner name: ASTERAND UK ACQUISITION LIMITED

Free format text: FORMER OWNER WAS: ASTERAND UK LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired